Form 4: John McCranie receives 40,878 RSUs at Enovix (ENVX)

Rhea-AI Filing Summary

Enovix Corp. director John Daniel McCranie received grants of restricted stock units (RSUs) totaling 40,878 shares on 08/12/2025, recorded on a Form 4 filed 08/26/2025. The filing shows two non‑derivative entries: 25,700 RSUs that will vest in 12 equal quarterly installments beginning August 12, 2025, and 15,178 RSUs with 25% vesting on November 12, 2025, February 12, 2026, May 12, 2026 and the earlier of June 12, 2026 or the company’s 2026 annual meeting (or immediately prior if the director does not stand for or is not re‑elected), subject to continued service.

The transactions are recorded at a $0 price per share, reflecting compensation grants rather than open‑market purchases, and the Form 4 was submitted by an attorney‑in‑fact for the reporting person.

Positive

• Clear disclosure of RSU awards with specific share counts and vesting schedules
• Alignment signal: awards are time‑based and conditioned on continued service, per the filing language

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Director received time‑based RSU grants with multi‑period vesting schedules to align service with equity compensation.

The Form 4 documents two RSU grants totaling 40,878 shares to director John Daniel McCranie, both awarded on 08/12/2025 and reported 08/26/2025. One grant vests in 12 equal quarterly installments, the other vests in four scheduled increments tied to specific dates or the 2026 annual meeting, conditional on continued service. The transactions are listed at $0, indicating issuance as compensation rather than market purchases. This is a routine director compensation disclosure; the filing provides clear vesting timelines but no cash amounts or valuation data.

Securities Analyst

TL;DR: Insider reported receipt of RSUs; disclosure is procedural and provides specific share counts and vesting dates.

The report details non‑derivative awards: 25,700 RSUs vesting quarterly over three years from the August 12, 2025 start date, and 15,178 RSUs vesting 25% on four specified dates or earlier upon the 2026 annual meeting condition. The Form indicates beneficial ownership post‑transactions of 40,878 RSU‑linked shares. The filing does not include exercise prices or cash consideration, only that the price is $0, consistent with RSU grants. No sales, purchases, or derivative transactions are reported in this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCCRANIE J DANIEL

(Last) (First) (Middle)

C/O ENOVIX CORPORATION

3501 W. WARREN AVENUE

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enovix Corp [ ENVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		A		25,700(1)	A	$0	25,700	D
Common Stock	08/12/2025		A		15,178(2)	A	$0	40,878(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares issuable upon the settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in 12 equal quarterly installments measured from August 12, 2025, the vesting commencement date, subject to the Reporting Person's continuous service through each applicable vesting date.

2. Reflects shares issuable on the settlement of RSUs granted to the Reporting Person. 25% of the RSUs will vest on each of November 12, 2025, February 12, 2026, May 12, 2026 and the earlier of (i) June 12, 2026; or (ii) the date of the Issuer's 2026 annual meeting of stockholders (or the date immediately preceding such date if the Reporting Person's service as a director ends at such meeting due to the director's failure to be re-elected or not standing for re-election), subject to the Reporting Person's continuous service through each applicable vesting date.

3. Includes 40,878 shares issuable upon the settlement of RSUs granted to the Reporting Person.

Remarks:

	/s/ Arthi Chakravarthy, Attorney-in-Fact for John Daniel McCranie	08/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Enovix director John Daniel McCranie receive on 08/12/2025 (ENVX)?

He received RSU grants totaling 40,878 shares (25,700 and 15,178 shares) as reported on the Form 4.

When do the RSUs granted to John Daniel McCranie vest?

25,700 RSUs vest in 12 equal quarterly installments from August 12, 2025; 15,178 RSUs vest 25% on each of Nov 12, 2025; Feb 12, 2026; May 12, 2026; and on or before Jun 12, 2026/the 2026 annual meeting, subject to continued service.

Was there any cash purchase price reported for the RSU grants?

No. The Form 4 lists a $0 price, indicating these were compensation grants (RSUs) rather than purchases.

How many shares does the reporting person beneficially own following these transactions?

The filing shows 40,878 shares issuable upon settlement of RSUs following the reported transactions.

Who signed and filed the Form 4 for John Daniel McCranie?

The Form 4 was signed by Arthi Chakravarthy, Attorney‑in‑Fact for John Daniel McCranie on 08/26/2025.